The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
schedule
11:00
visibility
3 views
Source: NPR News
newspaper
DW News 
